Dr. Kagihara is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1380 Lusitana St Ste 608
Honolulu, HI 96813Phone+1 808-532-0315
Education & Training
University of ColoradoFellowship, Hematology and Medical Oncology, 2018 - 2021
University of HawaiiChief Residency, Internal Medicine, 2017 - 2018- University of HawaiiResidency, Internal Medicine, 2014 - 2017
- University of Hawaii, John A. Burns School of MedicineClass of 2014
Loyola Marymount UniversityBS, Biology, Summa cum laude, 2006 - 2010
Certifications & Licensure
HI State Medical License 2014 - 2026
CO State Medical License 2018 - 2021- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Inductee Gold Humanism Honor Society
- Inductee Alpha Omega Alpha Honor Medical Society
Publications & Presentations
PubMed
- 7 citationsEvaluating anthracycline + taxane versus taxane-based chemotherapy in older women with node-negative triple-negative breast cancer: a SEER-Medicare studyAnna R Schreiber, Jodi A. Kagihara, Megan Eguchi, Peter Kabos, Christine M. Fisher
Breast Cancer Research and Treatment. 2021-10-27 - 4 citationsMoving Towards Targeted Therapies for Triple-Negative Breast CancerJodi A. Kagihara, Elena Shagisultanova, Anosheh Afghahi, Jennifer R. Diamond
Current Breast Cancer Reports. 2021-05-04 - 16 citationsNab-paclitaxel and atezolizumab for the treatment of PD-L1-positive, metastatic triple-negative breast cancer: review and future directionsJodi A. Kagihara, Michelle Andress, Jennifer R. Diamond
Expert Review of Precision Medicine and Drug Development. 2020-02-20
Abstracts/Posters
- Phase 1 study of OKI-179, an oral class 1-selective depsipeptide HDAC inhibitor, in patients with advanced solid tumors: Final results.Kagihara JA, Corr B, Pacheco J, Davis SL, Lieu C, Kim S, Jimeno A, Heim A, DeMattei JA, Gordon G, Triplett TA, Eckhardt SG, Winkler JD, Piscopio AD, Diamond JR., ASCO Annual Conference 2021
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
